Rare Mutations and Fusions Patient Gateway
LATEST UPDATES
-
New Insights in Treating Metastatic Lung Cancer from WCLC 2025
Read time: 3 minutes. For people with advanced or metastatic non-small cell lung cancer (NSCLC), the treatment landscape has changed dramatically in recent years. Researchers are... -
First Oral Targeted Therapy Approved for Advanced HER2+ NSCLC
On August 8, 2025, the US Food and Drug Administration (FDA) announced the accelerated approval of zongertinib (Hernexeos®) to treat patients with unresectable or metastatic non... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community...